Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Bristol-Myers Squibb Company rose $0.96 (2.1%) to $47.52 on average volume. Throughout the day, 6,255,951 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7,053,300 shares. The stock ranged in a price between $46.33-$47.55 after having opened the day at $46.78 as compared to the previous trading day's close of $46.56. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 175.1%, Discovery Laboratories ( DSCO), up 37.1%, Idera Pharmaceuticals ( IDRA), up 16.7% and Ambit Biosciences ( AMBI), up 12.4%.
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $77.1 billion and is part of the health care sector. Shares are up 43.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 10 rate it a hold. TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.